Article By:
EqualOcean
Saturday, July 9, 2022 7:20 PM EDT
InnoCare Pharma, which focuses on the treatment of cancer and autoimmune diseases, will look to further complete its product pipelines with the approval for its novel targeted protein degrader ICP-490.